Soluble TNFα blockade enhances trastuzumab deruxtecan antitumor effect in HER2-positive breast cancer model

被引：0
|
作者：
Bruni, Sofia
Mauro, Florencia
Proietti, Cecilia
Cordo-Russo, Rosalia
Schillaci, Roxana
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-12
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer
    Shimomura, Akihiko
    Takano, Toshimi
    Takahashi, Shunji
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Shinkai, Tetsu
    Kamio, Takahiro
    Kikumori, Kunika
    Kamiyama, Emi
    Fujisaki, Yoshihiko
    Saotome, Dan
    Yamashita, Toshinari
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 160 - 169
  • [42] Concurrent Use of Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer
    Bouziane, Jihane
    Loap, Pierre
    Cao, Kim
    Allali, Sofiane
    Gounane, Yacine
    Loganadane, Gokoulakrichenane
    Escalup, Laurence
    Pierga, Jean-Yves
    Kirova, Youlia
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (12): : 580 - 584
  • [43] Temsirolimus enhances the growth inhibitory effect of trastuzumab in HER2-positive breast cancer cell lines
    Kim, Elizabeth M. H.
    VanDusen, Hillary
    Lobocki, Catherine
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 211 (03) : S121 - S121
  • [44] Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
    Shanshan Hu
    Yilai Wu
    Jiajie Luan
    Shuowen Wang
    Guorong Fan
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 17933 - 17942
  • [45] Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Saura, Cristina
    Yamashita, Toshinari
    Kim, Sung-Bae
    Tamura, Kenji
    Chen, Shuquan
    Suto, Fumitaka
    Kuwahara, Yusuke
    Lee, Caleb C.
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
    Chen, Yuanping
    Liu, Chao
    Wen, Xinglin
    Wang, Chen
    He, Jing
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2024, 16 : 1277 - 1283
  • [47] Real World Data for Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases
    Toler, Andrew
    Bobolts, Laura R.
    Mangurian, Mark
    Pozotrigo, Melissa
    Wise, Corey
    Solomon, Hiywete
    Hartung, Nicole
    Makielski, Rory
    Marur, Shika
    Ravindranathan, Meera
    Marur, Shanthi
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
    Matsui, Chiaki
    Shibata, Nobuhiro
    Hirai, Chie
    Tada, Manami
    Kikawa, Yuichiro
    Sugie, Tomoharu
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 497 - 502
  • [49] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
    Masahiko Aoki
    Satoru Iwasa
    Narikazu Boku
    Gastric Cancer, 2021, 24 : 567 - 576
  • [50] Trastuzumab deruxtecan: Defining a novel systemic treatment standard for HER2-positive breast cancer brain metastases?
    Bartsch, Rupert
    Preusser, Matthias
    NEURO-ONCOLOGY, 2024, 26 (12) : 2157 - 2158
12345